Program

BIO VentureForum East Program  
(as of April 19, 2005, 2:30 p.m.)

Monday, May 9, 2005

4:00 p.m. – 7:00 p.m.   Registration Open                    
6:00 p.m. – 7:30 p.m.   Welcome Reception sponsored by SEBIO             
7:30 p.m. – 9:00 p.m.   VC Networking Dinner (by invitation only) sponsored by Georgia Research Alliance & Georgia Biomedical Partnership

Greetings from Morrie Ruffin, Vice President, Business Development, Biotechnology Industry Organization
and Mark G. Heesen, President, National Venture Capital Association

Tuesday, May 10, 2005
8:00 a.m. – 6:00 p.m.  Registration Open                    
7:30-8:00 a.m. - Continental Breakfast sponsored by Dechert, LLP
8:00 a.m. – 9:45 a.m.  Breakfast and Plenary Session

Welcome by James C. Greenwood, President & CEO, Biotechnology Industry Organization
Welcome by Georgia Governor Sonny Perdue

Venture Capital Investing Trends
 Sponsored by Rodman & Renshaw

This plenary session will feature a roundtable discussion with some of the leading venture capital investors.  Included are representatives from East and West Coast firms focused on early- and late-stage investments, as well as corporate venture capital.  The panel will discuss the current biotechnology investment climate, and identify the most important issues facing biotech CEOs looking for private financing.         

Panelists:
 John J. Borer, III, President, Rodman & Renshaw, LLC
Kelly Holman, Managing Director, Genesys Capital
Garheng Kong, General Partner, Intersouth Partners
Deepa Pakianathan, General Partner, Delphi Ventures
Mark Strobeck, Principal, SR One
Moderator : Russell M. Medford, MD, PhD, President & CEO, AtheroGenics, Inc.

10:00 a.m. – 12:00 p.m.  Company Presentations
10:15 a.m. – 12:15 p.m.  Breakout Sessions
10:30 a.m. – 12:00 p.m.  Workshop

Increasing Valuation Through Milestone Driven Development Strategy and Strategic Outsourcing
Sponsored by Fulcrum Pharma Developments

This workshop will address challenges faced by emerging pharma and biotech companies with limited development funds and internal resources.  Development strategy must connect product development activities with preclinical and clinical development plans in order to achieve development milestones and build investor confidence for subsequent funding rounds at increased valuation.  The panel will discuss issues including what activities and when to internalize versus outsource; regulatory agency interactions; clinical development plans tailored to strategy for out-license, partnering, or registration of the product; what are investors looking for when it comes to value creation and potential upside?  

Panelists:
 James J. Egan, JD, Senior Vice President, Business and Corporate Development, Idenix Pharmaceuticals
Marc-Henri Galleti,  Senior Vice President, Health Care, Pequot Ventures
Art Pappas, Managing General Partner, A. M. Pappas & Associates
Peter F. Young, President & CEO, AlphaVax Inc.
Moderator: Bruce J. McCreedy, PhD, CEO, Fulcrum Pharma Developments, Inc.

12:00 p.m. – 1:30 p.m.   Luncheon with Keynote Speaker sponsored by Pfizer, Inc.- "Technology: The Path to Eliminating Suffering and Death Due to Cancer"
 Andrew C. von Eschenbach, Director, National Cancer Institute

1:45 p.m. – 3:15 p.m.  Company Presentations
1:45 p.m. – 3:15 p.m.  Workshop

Building Bridges Between University Technologies, Industry, and the Investment Community
Sponsored by Emory University, Duke University, University of North Carolina at Chapel Hill, University of Florida and Vanderbilt University.

University discoveries are often at an embryonic stage of development.  Funding to pursue proof of concept for these technologies has always been difficult to secure.  This problem--in combination with the expectations of venture capital and industry that technology be "better developed"-- creates a funding gap.  Like all stages of the innovation pathway, research support and capital are critical to achieve proof of concept.  This panel will analyze this funding gap as well as explore creative mechanisms to secure a contiguous funding pathway. 

Panelists:
 David L. Day, Director, Office of Technology Licensing and Sid Martin Biotechnology Development Incubator, University of Florida
Teo Dagi, Managing Partner, Cordova Ventures
Anna Hall, Senior Director, Business Development, Genentech, Inc.
Anthony J. Natale MD, MBA, Venture Partner, MDS Capital
Christopher F. Reilly, PhD, Vice President & Head, Global Discovery Venture, AstraZeneca
Moderator: Todd Sherer, Assistant Vice President, Research & Director, Office of Technology Transfer, Emory University

2:00 p.m. – 5:15 p.m.  Breakout Sessions
3:30 p.m. – 5:00 p.m.  Company Presentations
3:30 p.m. – 5:00 p.m.  Workshop

IP to Impress the VC
Sponsored by Catalina & Associates

Everyone knows that intellectual property protection, and in particular, patent protection, is a critical factor in the commercial success of biotechnology companies.  Patents enable biotech companies to create and to maintain a competitive advantage.  Just as importantly, a strong patent portfolio is also critical in attracting venture capital investment. What do VCs and Big Pharma look for in evaluating an emerging biotech’s IP portfolio?  What strategies should early stage biotech companies implement to best leverage their IP to attract needed capital?  How should a start-up biotech company prepare for an IP due diligence?  What can a biotech company do to present its IP portfolio in its best light?  These are some of the questions that will be answered in this year’s IP Workshop. 

Panelists:
Kathryne F. Carr, Managing Director, Tall Oaks Capital Partners
Dennis L. McWilliams , Entrepreneur in Residence, PTV Sciences, LP
Carole Nuechterlein, Head, Venture Investments, F.Hoffmann-La Roche Ltd.
Peter Tu, Associate General Counsel & Senior Director, Intellectual Property, Savient Pharmaceuticals, Inc.
Moderator: Richard A. Catalina, Jr., Esq., Managing Attorney, Catalina & Associates, A Professional Corporation

6:30 p.m. – 9:30 p.m. Gala Reception at Sambuca 

Sponsored by Emory University, Duke University, University of North Carolina at Chapel Hill, University of Florida and Vanderbilt University.

Wednesday, May 11, 2005
8:00 a.m. – 6:00 p.m.  Registration Open                        
7:30-8:00 a.m. - Continental Breakfast sponsored by Bioworld
8:00 a.m. – 9:45 a.m.  Breakfast & Plenary Session        

Industry Trends for In-licensing and Partnering
 Sponsored by Georgia Department of Economic Development and Georgia Allies

Pharmaceutical companies and large- and mid-cap biotech firms recognize the growing importance of working with venture-backed companies to address the discovery and early development components of their pipelines. For most private companies, deciding who to collaborate with and how to structure such a partnership may have even more impact on the success of their company than the FDA’s approval of their product. Many early-stage biotech companies look to partnership strategies to share development expenses and to monetize both core and non-core assets.   While these partnerships may alleviate near-term cash concerns for the company, many companies overlook the long-term consequences of the partnering terms effects and how the terms will affect the future strategy and valuation of the company. This plenary session will feature a roundtable discussion with pharmaceutical and biotech executives who will discuss their own pipeline sustainability requirements and examine how collaborations can impact their needs. They will also address the question of how large firms should build relationships with early stage firms.

Panelists:
Donald L. Drakeman, President & CEO; Medarex, Inc.
Robert J. Gould, PhD; Vice President, Licensing and External Research, Boston; Merck Research Labs
John D. Mendlein PhD, JD, Chairman & CEO, Affinium Pharmaceuticals
Herbert S Ormsbee, PhD, Senior Director, Licensing & Development, Pfizer Inc.
John P. Richard, President, BioGrowth
Moderator: Kristopher D. Ford, UCB Corporate Strategy & Business Development, UCB Pharma Inc.

10:00 a.m. – 12:00 p.m.  Company Presentations
10:00 a.m. – 12:00 p.m.  Workshop

Supporting the Development of Medical Devices:  The Evolving Role of Large Companies, Early-Stage Companies and Private Investors
Sponsored by Sutherland Asbill & Brennan, LLP

Representatives of big business and the venture capital community will share the platform with an early-stage medical device company to discuss financing alternatives available--or not available--to early stage companies.  What are the risks and rewards of inviting one or the other into your company?  What do big businesses and VCs expect for their investment of time and money?  What recent trends strengthen or weaken the hand of an early-stage company in this process? 

Panelists:
William Hawkins, President & COO, Medtronic, Inc.
Zubeen Shroff, General Partner, Galen Partners
David Stern, President & CEO, CardioMEMS, Inc.
Moderator: Phillp H. Moise, Partner, Sutherland Asbill & Brennan, LLP

10:15 a.m. – 12:15 p.m.  Breakout Sessions

12:00 p.m. – 1:30 p.m.   Luncheon with Keynote Speaker sponsored by Merck & Co. -   "Managing Transformative Growth"
 Thomas H. McLain, Chairman, CEO and President, Nabi Biopharmaceuticals

1:45 p.m. – 3:15 p.m.     Company Presentations
1:45 p.m. – 3:15 p.m.     Workshop

The Art of the Deal: Raising Funds and Creating Vehicles for Venture Investments and Company Mergers
Sponsored by King & Spalding

This workshop will take a practical look at how to raise funds and create optimal funding structures for venture investments and mergers in the pharmaceutical and biotechnology arenas. A panel of experienced venture capital specialists will offer insights on the "personalities" of different venture capital firms, when the time is right to approach a VC, what are the most successful kinds of approaches, valuation, and variations in venture deal structures. Panelists will also address the fundamentals of structuring and financing mergers and acquisitions in the biotech and life sciences industries including strategic “fit,” integration, use of equity, and use of the public markets for financing.

Panelists:
Gaurav Aggarwal, M.D., Associate, JP Morgan Partners
Brian Halack, Ph.D., Principal, Domain Associates, LLC
Anders Hove, General Partner, Venrock Associates
William D. Johnston, Ph.D., President and CEO, Inhibitex
Roth Kehoe, Esq., Partner, King & Spalding
Moderator: Sherry M. Knowles, Esq. Partner, King & Spalding

2:00 p.m. – 5:15 p.m.     Breakout Sessions
3:30 p.m. – 5:00 p.m.     Company Presentations
5:00 p.m. – 7:00 p.m.     Closing Reception                      
 

A graphic version of this information is available click here